JPRN-jRCT2080221162未知3 期
A double-blind confirmatory study for AD-810N (zonisamide) in patients with Parkinson's disease (Phase III)
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Patients with Parkinson's disease who meet the following criteria
- •- Patients who are effective in the treatment of L-DOPA single-agent or L-DOPA/DCI combination of drugs when initiated treatment
- •- Patients who are taking L-DOPA/DCI combination of drugs continuously for more than 6 months
- •- Patients who have developed the wearing-off phenomenon
排除标准
- •- Patients with epilepsy
- •- Patients who are taking L-DOPA single-agent
- •- Patients with a history of treatment with zonisamide
研究者
相似试验
未知
2 期
An Exploratory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies (Phase 2 study)JPRN-jRCT2080221994Dainippon Sumitomo Pharma Co., Ltd.150
未知
3 期
Confirmatory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies.JPRN-jRCT2080222787Sumitomo Dainippon Pharma Co., Ltd.300
未知
3 期
Double-blind confirmatory study of AD-5423 (blonanserin) in patients with schizophrenia [Phase 3 study]schizophreniaJPRN-jRCT2080220098Dainippon Sumitomo Pharma Co., Ltd.
招募中
3 期
A Study to Evaluate the Efficacy and Safety of AD-218Mixed DyslipidemiaNCT05400317Addpharma Inc.520
进行中（未招募）
1 期
ADP-A2M4CD8 in advanced cancersadvanced esophageal or esophagogastric junction (EGJ) cancersMedDRA version: 21.0Level: LLTClassification code 10015362Term: Esophageal cancerSystem Organ Class: 100000004864EUCTR2020-005802-24-ESAdaptimmune LLC45